131 related articles for article (PubMed ID: 37767643)
41. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
[TBL] [Abstract][Full Text] [Related]
42. Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.
Bormann M; van de Sand L; Witzke O; Krawczyk A
Klin Monbl Augenheilkd; 2021 May; 238(5):569-578. PubMed ID: 34020485
[TBL] [Abstract][Full Text] [Related]
43. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
44. Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks.
Dhawan M; Priyanka ; Parmar M; Angural S; Choudhary OP
Int J Surg; 2022 Jan; 97():106204. PubMed ID: 34974199
[TBL] [Abstract][Full Text] [Related]
45. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
Focosi D; Franchini M
Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
[TBL] [Abstract][Full Text] [Related]
46. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
Gastinne T; Le Bourgeois A; Coste-Burel M; Guillaume T; Peterlin P; Garnier A; Imbert BM; Drumel T; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Tessoulin B; Jullien M; Vanthygem S; Béné MC; Moreau P; Le Gouill S; Chevallier P
Br J Haematol; 2022 Jan; 196(2):360-362. PubMed ID: 34476803
[No Abstract] [Full Text] [Related]
47. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
[TBL] [Abstract][Full Text] [Related]
48. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity.
Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N
J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533
[TBL] [Abstract][Full Text] [Related]
49. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.
Passweg JR; Baldomero H; Ciceri F; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; McLornan DP; Neven B; de Latour RP; Perić Z; Ruggeri A; Snowden JA; Sureda A
Bone Marrow Transplant; 2023 Jun; 58(6):647-658. PubMed ID: 36879108
[TBL] [Abstract][Full Text] [Related]
50. Predominantly defective CD8
Taus E; Shino MY; Ibarrondo FJ; Hausner MA; Hofmann C; Yang OO
J Transl Med; 2023 Jun; 21(1):374. PubMed ID: 37291575
[TBL] [Abstract][Full Text] [Related]
51. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
52. Development of T-cell immunity in a liver and hematopoietic stem cell transplant recipient following coronavirus disease 2019 infection.
Soni M; Migliori E; Assal A; Chan HT; Ciubotariu R; Pan JB; Cicero K; Pereira M; Mapara MY; Muranski P
Cytotherapy; 2021 Nov; 23(11):980-984. PubMed ID: 34183244
[TBL] [Abstract][Full Text] [Related]
53. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals.
Healy K; Pin E; Chen P; Söderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Österborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Loré K; Hellström C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren HG; Hober S; Nilsson P; Aleman S; Sällberg Chen M
Med; 2022 Feb; 3(2):137-153.e3. PubMed ID: 35075450
[TBL] [Abstract][Full Text] [Related]
54. Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant.
Lazzari L; Oltolini C; Ciceri F; Giglio F
BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34667047
[TBL] [Abstract][Full Text] [Related]
55. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
Wang Y; Huo P; Dai R; Lv X; Yuan S; Zhang Y; Guo Y; Li R; Yu Q; Zhu K
Int Immunopharmacol; 2021 Feb; 91():107262. PubMed ID: 33338863
[TBL] [Abstract][Full Text] [Related]
56. Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications.
Spinicci M; Mazzoni A; Coppi M; Antonelli A; Salvati L; Maggi L; Basile G; Graziani L; Di Lauria N; Di Pilato V; Kiros ST; Beccastrini E; Saccardi R; Angileri M; Cecchi M; Cusi MG; Rossolini GM; Annunziato F; Bartoloni A; Parronchi P
J Clin Immunol; 2022 Oct; 42(7):1371-1378. PubMed ID: 35779200
[TBL] [Abstract][Full Text] [Related]
57. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).
Malsy J; Veletzky L; Heide J; Hennigs A; Gil-Ibanez I; Stein A; Lütgehetmann M; Rosien U; Jasper D; Peine S; Hiller J; Haag F; Schmiedel S; Huber S; Jordan S; Addo MM; Schulze Zur Wiesch J
Clin Infect Dis; 2021 Dec; 73(11):e4020-e4024. PubMed ID: 33103195
[TBL] [Abstract][Full Text] [Related]
58. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
He X; Zeng XX
Drug Des Devel Ther; 2022; 16():951-972. PubMed ID: 35386853
[TBL] [Abstract][Full Text] [Related]
59. Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.
Thümmler L; Lindemann M; Horn PA; Lenz V; Konik M; Gäckler A; Boss K; Theodoropoulos F; Besa V; Taube C; Brenner T; Witzke O; Krawczyk A; Rohn H
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680159
[TBL] [Abstract][Full Text] [Related]
60. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.
Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Brooks AES
Expert Rev Clin Immunol; 2022 Jun; 18(6):557-565. PubMed ID: 35510369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
